168 related articles for article (PubMed ID: 36180600)
1. IKZF3 amplification frequently occurs in HER2-positive breast cancer and is a potential therapeutic target.
Lin CY; Yu CJ; Shen CI; Liu CY; Chao TC; Huang CC; Tseng LM; Lai JI
Med Oncol; 2022 Sep; 39(12):242. PubMed ID: 36180600
[TBL] [Abstract][Full Text] [Related]
2. Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer.
Hergueta-Redondo M; Sarrio D; Molina-Crespo Á; Vicario R; Bernadó-Morales C; Martínez L; Rojo-Sebastián A; Serra-Musach J; Mota A; Martínez-Ramírez Á; Castilla MÁ; González-Martin A; Pernas S; Cano A; Cortes J; Nuciforo PG; Peg V; Palacios J; Pujana MÁ; Arribas J; Moreno-Bueno G
Oncotarget; 2016 Aug; 7(35):56295-56308. PubMed ID: 27462779
[TBL] [Abstract][Full Text] [Related]
3. Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).
Cocco E; Javier Carmona F; Razavi P; Won HH; Cai Y; Rossi V; Chan C; Cownie J; Soong J; Toska E; Shifman SG; Sarotto I; Savas P; Wick MJ; Papadopoulos KP; Moriarty A; Cutler RE; Avogadri-Connors F; Lalani AS; Bryce RP; Chandarlapaty S; Hyman DM; Solit DB; Boni V; Loi S; Baselga J; Berger MF; Montemurro F; Scaltriti M
Sci Signal; 2018 Oct; 11(551):. PubMed ID: 30301790
[TBL] [Abstract][Full Text] [Related]
4. RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer.
Singh H; Sahgal P; Kapner K; Corsello SM; Gupta H; Gujrathi R; Li YY; Cherniack AD; El Alam R; Kerfoot J; Andrews E; Lee A; Nambiar C; Hannigan AM; Remland J; Brais L; Leahy ME; Rubinson DA; Schlechter BL; Meyerson M; Kuang Y; Paweletz CP; Lee JK; Quintanilha JCF; Aguirre AJ; Perez KJ; Huffman BM; Rossi H; Abrams TA; Kabraji S; Trusolino L; Bertotti A; Sicinska ET; Parikh AR; Wolpin BM; Schrock AB; Giannakis M; Ng K; Meyerhardt JA; Hornick JL; Sethi NS; Cleary JM
Clin Cancer Res; 2024 Apr; 30(8):1669-1684. PubMed ID: 38345769
[TBL] [Abstract][Full Text] [Related]
5. Prognostic relevance of gene amplifications and coamplifications in breast cancer.
Al-Kuraya K; Schraml P; Torhorst J; Tapia C; Zaharieva B; Novotny H; Spichtin H; Maurer R; Mirlacher M; Köchli O; Zuber M; Dieterich H; Mross F; Wilber K; Simon R; Sauter G
Cancer Res; 2004 Dec; 64(23):8534-40. PubMed ID: 15574759
[TBL] [Abstract][Full Text] [Related]
6. Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies.
Shiu KK; Wetterskog D; Mackay A; Natrajan R; Lambros M; Sims D; Bajrami I; Brough R; Frankum J; Sharpe R; Marchio C; Horlings H; Reyal F; van der Vijver M; Turner N; Reis-Filho JS; Lord CJ; Ashworth A
Oncogene; 2014 Jan; 33(5):619-31. PubMed ID: 23334330
[TBL] [Abstract][Full Text] [Related]
7. Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.
Kurozumi S; Alsaleem M; Monteiro CJ; Bhardwaj K; Joosten SEP; Fujii T; Shirabe K; Green AR; Ellis IO; Rakha EA; Mongan NP; Heery DM; Zwart W; Oesterreich S; Johnston SJ
Breast Cancer Res; 2020 Aug; 22(1):85. PubMed ID: 32782013
[TBL] [Abstract][Full Text] [Related]
8. High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer.
Staaf J; Jönsson G; Ringnér M; Vallon-Christersson J; Grabau D; Arason A; Gunnarsson H; Agnarsson BA; Malmström PO; Johannsson OT; Loman N; Barkardottir RB; Borg A
Breast Cancer Res; 2010; 12(3):R25. PubMed ID: 20459607
[TBL] [Abstract][Full Text] [Related]
9. Role of MEL-18 Amplification in Anti-HER2 Therapy of Breast Cancer.
Lee JY; Joo HS; Choi HJ; Jin S; Kim HY; Jeong GY; An HW; Park MK; Lee SE; Kim WS; Son T; Min KW; Oh YH; Kong G
J Natl Cancer Inst; 2019 Jun; 111(6):609-619. PubMed ID: 30265336
[TBL] [Abstract][Full Text] [Related]
10. Monosomy 17 in potentially curable HER2-amplified breast cancer: prognostic and predictive impact.
Page DB; Wen H; Brogi E; Dure D; Ross D; Spinelli KJ; Patil S; Norton L; Hudis C; McArthur HL
Breast Cancer Res Treat; 2018 Jan; 167(2):547-554. PubMed ID: 28986743
[TBL] [Abstract][Full Text] [Related]
11. Intrinsic HER2 V777L mutation mediates resistance to trastuzumab in a breast cancer patient.
Hirotsu Y; Nakagomi H; Amemiya K; Oyama T; Inoue M; Mochizuki H; Omata M
Med Oncol; 2017 Jan; 34(1):3. PubMed ID: 27900589
[TBL] [Abstract][Full Text] [Related]
12. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
13. Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases.
Priedigkeit N; Hartmaier RJ; Chen Y; Vareslija D; Basudan A; Watters RJ; Thomas R; Leone JP; Lucas PC; Bhargava R; Hamilton RL; Chmielecki J; Puhalla SL; Davidson NE; Oesterreich S; Brufsky AM; Young L; Lee AV
JAMA Oncol; 2017 May; 3(5):666-671. PubMed ID: 27926948
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab.
Lee HJ; Kim JY; Park SY; Park IA; Song IH; Yu JH; Ahn JH; Gong G
Am J Clin Pathol; 2015 Oct; 144(4):570-8. PubMed ID: 26386078
[TBL] [Abstract][Full Text] [Related]
15. Quantitative assessment of HER2 amplification in HER2-positive breast cancer: its association with clinical outcomes.
Xuan Q; Ji H; Tao X; Xu Y; Zhang Q
Breast Cancer Res Treat; 2015 Apr; 150(3):581-8. PubMed ID: 25762478
[TBL] [Abstract][Full Text] [Related]
16. HER2 amplification level is not a prognostic factor for HER2-positive breast cancer with trastuzumab-based adjuvant treatment: a systematic review and meta-analysis.
Xu QQ; Pan B; Wang CJ; Zhou YD; Mao F; Lin Y; Guan JH; Shen SJ; Zhang XH; Xu YL; Zhong Y; Wang XJ; Zhang YN; Sun Q
Oncotarget; 2016 Sep; 7(39):63571-63582. PubMed ID: 27566580
[TBL] [Abstract][Full Text] [Related]
17. High-level ERBB2 gene amplification is associated with a particularly short time-to-metastasis, but results in a high rate of complete response once trastuzumab-based therapy is offered in the metastatic setting.
Fuchs EM; Köstler WJ; Horvat R; Hudelist G; Kubista E; Attems J; Zielinski CC; Singer CF
Int J Cancer; 2014 Jul; 135(1):224-31. PubMed ID: 24311197
[TBL] [Abstract][Full Text] [Related]
18. Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer.
Choi JH; Jeon CW; Kim YO; Jung S
Medicine (Baltimore); 2020 Nov; 99(46):e23053. PubMed ID: 33181670
[TBL] [Abstract][Full Text] [Related]
19. Genome profiling of ERBB2-amplified breast cancers.
Sircoulomb F; Bekhouche I; Finetti P; Adélaïde J; Ben Hamida A; Bonansea J; Raynaud S; Innocenti C; Charafe-Jauffret E; Tarpin C; Ben Ayed F; Viens P; Jacquemier J; Bertucci F; Birnbaum D; Chaffanet M
BMC Cancer; 2010 Oct; 10():539. PubMed ID: 20932292
[TBL] [Abstract][Full Text] [Related]
20. Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.
Ross JS; Fakih M; Ali SM; Elvin JA; Schrock AB; Suh J; Vergilio JA; Ramkissoon S; Severson E; Daniel S; Fabrizio D; Frampton G; Sun J; Miller VA; Stephens PJ; Gay LM
Cancer; 2018 Apr; 124(7):1358-1373. PubMed ID: 29338072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
